Results 11 to 20 of about 5,281 (177)
Urate lowering therapy in primary care: rheum for improvement [PDF]
Exploration of Musculoskeletal DiseasesPrimary care physicians (PCPs) play a critical role in the management of gout worldwide. However, significant gaps in gout care persist, underscoring the need for improved approaches to its management.
Emilie Schurenberg +2 more
doaj +2 more sources
Perceptions About Asymptomatic Hyperuricemia and Views About Urate-Lowering Therapy in People With Asymptomatic Hyperuricemia. [PDF]
Arthritis Care Res (Hoboken)Objective Asymptomatic hyperuricemia is a precursor of gout and is also associated with cardiovascular disease and chronic kidney disease. The aim of this study was to understand perceptions about asymptomatic hyperuricemia and views about urate‐lowering therapy in people with asymptomatic hyperuricemia. Methods Participants in a multinational study of
Dalbeth N +19 more
europepmc +2 more sources
Frontiers in Pharmacology, 2022 Dysfunctional missense variant of organic anion transporter 10 (OAT10/SLC22A13), rs117371763 (c.1129C>T; p.R377C), is associated with a lower susceptibility to gout.
Yu Toyoda +15 more
doaj +1 more source
The many faces of gout: modern treatment concepts
Клинический разбор в общей медицине, 2021 Gout is a systemic disease caused by the deposition of monosodium urate crystals in various tissues and organs with the subsequent development of autoinflammation.
Irina N. Bobkova, Elena S. Kamyshova
doaj +1 more source
Urate-lowering drugs in the treatment of gout: The unknown about the known
Научно-практическая ревматология, 2021 The main direction of drug therapy for gout and other diseases associated with hyperuricemia is the long-term use of drugs aimed at correcting the level of uric acid.
T. S. Panevin +2 more
doaj +1 more source
Arthritis & Rheumatology, 2023 ObjectiveGout is associated with a higher risk of fracture; however, findings on the associations of hyperuricemia and urate‐lowering therapy (ULT) with the risk of fracture have been inconsistent. We examined whether lowering serum urate (SU) levels with ULT to a target level (i.e., <360 μmoles/liter) reduces the risk of fracture among individuals ...
Jie Wei +8 more
openaire +4 more sources
Estradiol regulates intestinal ABCG2 to promote urate excretion via the PI3K/Akt pathway
Nutrition & Metabolism, 2021 Objectives The study of sex differences in hyperuricemia can provide not only a theoretical basis for this clinical phenomenon but also new therapeutic targets for urate-lowering therapy.
Lei Liu +5 more
doaj +1 more source
Cardiac and renal protective effects of urate-lowering therapy [PDF]
Rheumatology, 2017 Patients with gout often have co-morbidities such as cardiovascular disease, renal failure and metabolic syndrome components. Some studies, but not all, have suggested that hyperuricaemia and gout are associated with increased risk of myocardial infarction, renal failure and death primarily because of increased risk of cardiovascular events. Therefore,
Pascal, Richette +2 more
openaire +2 more sources
Contentious Issues in Gout Management: The Story so Far
Open Access Rheumatology: Research and Reviews, 2021 Mohamed Talaat,1 Kyle Park,1 Naomi Schlesinger2 1Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA; 2Division of Rheumatology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 08903-0019 ...
Talaat M, Park K, Schlesinger N
doaj
Bariatric surgery as urate-lowering therapy in severe obesity [PDF]
Annals of the Rheumatic Diseases, 2014 Gout represents a metabolically driven inflammatory arthropathy, which could be substantially influenced by adiposity and lifestyle risk factors. As such, influenced by the trends in lifestyle factors associated with Westernisation,1 ,2 gout prevalence has increased in the last few decades worldwide (eg, 3.9% of US adults (8.3 million) in 2007–20083).4
Hyon K, Choi, Yuqing, Zhang
openaire +2 more sources